Cargando…

Clinical aspects of a large group of adults with Angelman syndrome

Descriptions of the clinical features of Angelman syndrome (AS) have mainly been focused on children. Here, we describe the evolution of the clinical phenotypes of AS in adulthood, using clinical data from 95 individuals (mean age 31.6 years, median 29.0 years, range 18–83 years), with genetically c...

Descripción completa

Detalles Bibliográficos
Autores principales:	den Besten, Inge, de Jong, Rianne F., Geerts‐Haages, Amber, Bruggenwirth, Hennie T., Koopmans, Marije, Brooks, Alice, Elgersma, Ype, Festen, Dederieke A. M., Valstar, Marlies J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756639/ https://www.ncbi.nlm.nih.gov/pubmed/33108066 http://dx.doi.org/10.1002/ajmg.a.61940

Ejemplares similares

A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome
por: Geerts‐Haages, Amber, et al.
Publicado: (2020)

UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome
por: Elgersma, Ype, et al.
Publicado: (2021)

Enhanced Transmission at the Calyx of Held Synapse in a Mouse Model for Angelman Syndrome
por: Wang, Tiantian, et al.
Publicado: (2018)

From first report to clinical trials: a bibliometric overview and visualization of the development of Angelman syndrome research
por: Zampeta, F. Isabella, et al.
Publicado: (2022)

Calmodulin kinase II regulates amphetamine-induced reverse transport in the dopamine transporter: implications for the importance of the dopamine transporter in Angelman syndrome
por: Steinkellner, Thomas, et al.
Publicado: (2010)

Multidimensional analysis of behavior predicts genotype with high accuracy in a mouse model of Angelman syndrome
por: Tanas, Joseph K., et al.
Publicado: (2022)

The Hippocampal Response to Acute Corticosterone Elevation Is Altered in a Mouse Model for Angelman Syndrome
por: Viho, Eva M. G., et al.
Publicado: (2022)

Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome
por: Sonzogni, Monica, et al.
Publicado: (2020)

Hyperphagia, Growth, and Puberty in Children with Angelman Syndrome
por: Bindels-de Heus, Karen G. C. B., et al.
Publicado: (2023)

Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes
por: Sonzogni, Monica, et al.
Publicado: (2019)

An overview of health issues and development in a large clinical cohort of children with Angelman syndrome
por: Bindels‐de Heus, Karen G. C. B., et al.
Publicado: (2019)

Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations
por: Bossuyt, Stijn N V, et al.
Publicado: (2021)

A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants
por: Sonzogni, Monica, et al.
Publicado: (2018)

Angelman syndrome: review of clinical and molecular aspects
por: Bird, Lynne M
Publicado: (2014)

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model
por: Milazzo, Claudia, et al.
Publicado: (2021)

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
por: Valstar, Marlies J., et al.
Publicado: (2010)

Ca(2+)/Calmodulin-dependent Protein Kinase IIα (αCaMKII) Controls the Activity of the Dopamine Transporter: IMPLICATIONS FOR ANGELMAN SYNDROME
por: Steinkellner, Thomas, et al.
Publicado: (2012)

Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice
por: Judson, Matthew C., et al.
Publicado: (2021)

O.2.1-4 Physical activity program for people with intellectual disability: results from an implementation study
por: Wouters, Marieke, et al.
Publicado: (2023)

Communication‐related assessments in an Angelman syndrome mouse model
por: Perrino, Peter A., et al.
Publicado: (2020)

Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial
por: Beumer, Sylvie, et al.
Publicado: (2021)

Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by UBE3A and is involved in Angelman syndrome pathophysiology
por: Pandya, Nikhil J., et al.
Publicado: (2021)

Effectiveness of medication reviews in identifying and reducing medication‐related problems among people with intellectual disabilities: A systematic review
por: Nabhanizadeh, Amal, et al.
Publicado: (2019)

Angelman Syndrome and Angelman-like Syndromes Share the Same Calcium-Related Gene Signatures
por: Panov, Julia, et al.
Publicado: (2021)

Epilepsy in patients with Angelman syndrome
por: Fiumara, Agata, et al.
Publicado: (2010)

Neurodevelopmental Underpinnings of Angelman Syndrome
por: Li, Guohui, et al.
Publicado: (2014)

Angelman syndrome and anaesthetic considerations
por: Agarwal, Jyotsna, et al.
Publicado: (2017)

A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry
por: Napier, Kathryn R., et al.
Publicado: (2017)

A brain proteomic investigation of rapamycin effects in the Tsc1(+/−) mouse model
por: Wesseling, Hendrik, et al.
Publicado: (2017)

A Dutch Perspective on Two Health Related Issues Regarding Children and Adolescents with Intellectual Disabilities
por: Moonen, Xavier, et al.
Publicado: (2022)

Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman Syndrome Natural History Study
por: Khan, Nasreen, et al.
Publicado: (2019)

Behavior and neuropsychiatric manifestations in Angelman syndrome
por: Pelc, Karine, et al.
Publicado: (2008)

Epilepsy in Korean patients with Angelman syndrome
por: Park, Sung-Hee, et al.
Publicado: (2012)

Angelman Syndrome: A Case Report
por: Ashrafzadeh, Farah, et al.
Publicado: (2016)

Genotype–Phenotype Correlations in Angelman Syndrome
por: Yang, Lili, et al.
Publicado: (2021)

Stem cell models of Angelman syndrome
por: Camões dos Santos, João, et al.
Publicado: (2023)

Determining Frailty in People With Intellectual Disabilities in the COVID‐19 Pandemic
por: Festen, Dederieke A. M., et al.
Publicado: (2021)

Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders
por: Ottenhoff, Myrthe J., et al.
Publicado: (2020)

The effect of bright light therapy on depressive symptoms in adults with intellectual disabilities: Results of a multicentre randomized controlled trial
por: Hamers, Pauline C. M., et al.
Publicado: (2020)

Angelman syndrome and isovaleric acidemia: What is the link?
por: Lambrecht, Alix, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ujjdl8b2oiufpbsvo85fkjpbmd